Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Metabolic Syndrome. According to GlobalData, Phase II drugs for Metabolic Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Monlunabant LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monlunabant overview
Monlunabant is under development for the treatment of type I diabetes, asthma, pre-diabetes/impaired glucose tolerance, abdominal obesity, hypertriglyceridemia, diabetic nephropathy, type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity and metabolic syndrome. The drug candidates are administered through oral route. They act by targeting cannabinoid receptor 1 (CB1R).
Inversago Pharma overview
Inversago Pharma is a preclinical-stage biotech company. The company develops peripherally-restricted cannabinoid receptor 1, a G protein-coupled cannabinoid receptor that is encoded by the CNR1 gene for the treatment of Prader-Willi Syndrome, Type-1 Diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis.
For a complete picture of Monlunabant’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
